Chugai Pharmaceutical Co., Ltd.

Research Chugai Pharmaceutical Co., Ltd. (4519) on Bullrun: market cap JPY 12.40T, P/E 28.6, dividend yield 1.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• Ticker4519
• ExchangeTSE
• CountryJapan
• SectorHealthcare
• IndustryDrug Manufacturers - General
• CurrencyJPY
• Market capJPY 12.40T
• P/E28.6
• Dividend yield1.7%
• Financial periodFY2025
• RevenueJPY 1.26T
• Revenue growth7.5%
• Free cash flowJPY 274.67B
• Gross margin71.1%

Valuation Snapshot

latest market cap is JPY 12.40T; P/E is 28.6; dividend yield is 1.7%.

About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant;

Frequently asked questions

What is Chugai Pharmaceutical Co., Ltd.'s market cap?

Chugai Pharmaceutical Co., Ltd.'s market capitalization is JPY 12.40T.

What is Chugai Pharmaceutical Co., Ltd.'s P/E ratio?

Chugai Pharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 28.6.

Does Chugai Pharmaceutical Co., Ltd. pay a dividend?

Chugai Pharmaceutical Co., Ltd. has a dividend yield of 1.7%.

What does Chugai Pharmaceutical Co., Ltd. do?

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.